Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Double Bond Pharmaceutical International

0.20 SEK

+23.69 %

Less than 1K followers

DBP B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+23.69 %
+96.10 %
+57.65 %
-21.39 %
-46.41 %
-57.01 %
-54.10 %
-89.67 %
-93.11 %

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.

Read more
Market cap
41.36M SEK
Turnover
511K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Press release6/24/2025, 6:00 AM

DBP: Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053

Double Bond Pharmaceutical International
Press release6/17/2025, 8:59 AM

DBP: Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053

Double Bond Pharmaceutical International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.